All Stories

  1. The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents

    Article • Scientific Reports, December 2019, Springer Science + Business Media

    Dr Guy Griebel

  2. The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents

    Article • Scientific Reports, February 2018, Springer Science + Business Media

    Dr Guy Griebel

  3. Creativity in large pharmaceutical research organizations: unleash the hungry drug hunter

    Article • British Journal of Pharmacology, April 2017, Wiley

    Dr Guy Griebel

  4. The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia

    Article • Scientific Reports, October 2016, Springer Science + Business Media

    Dr Guy Griebel

  5. Neuropeptide Receptor Ligands for the Treatment of Schizophrenia: Focus on Neurotensin and Tachykinins

    Article • Current Pharmaceutical Design, August 2015, Bentham Science Publishers

    Dr Guy Griebel

  6. Long-lasting memory abnormalities following exposure to the mouse defense test battery: An animal model of PTSD

    Article • Physiology & Behavior, July 2015, Elsevier

    Dr Guy Griebel

  7. Pharmacology, Biochemistry and Behavior: The 2015 Transition

    Article • Pharmacology Biochemistry and Behavior, April 2015, Elsevier

    Dr Guy Griebel

  8. The CRF1 receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: Comparison with paroxetine and d-cycloserine

    Article • Behavioural Brain Research, February 2015, Elsevier

    Dr Guy Griebel

  9. Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents

    Article • Scientific Reports, January 2015, Nature

    Dr Guy Griebel

  10. Tachykinins

    Article • January 2015, Springer Science + Business Media

    Dr Guy Griebel

  11. Optogenetics to study the circuits of fear- and depression-like behaviors: A critical analysis

    Article • Pharmacology Biochemistry and Behavior, July 2014, Elsevier

    Dr Guy Griebel

  12. Mood and Anxiety Disorders

    Article • June 2014, Wiley

    Dr Guy Griebel

  13. Mice Deficient in Cryptochrome 1 (Cry1−/−) Exhibit Resistance to Obesity Induced by a High-Fat Diet

    Article • Frontiers in Endocrinology, April 2014, Frontiers

    Dr Guy Griebel

  14. Tachykinins

    Article • January 2014, Springer Science + Business Media

    Dr Guy Griebel

  15. Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep–wake disorders

    Article • Bioorganic & Medicinal Chemistry Letters, November 2013, Elsevier

    Dr Guy Griebel

  16. Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats

    Article • Behavioural Pharmacology, October 2013, Wolters Kluwer Health

    Dr Guy Griebel

  17. 50 years of hurdles and hope in anxiolytic drug discovery

    Article • Nature Reviews Drug Discovery, August 2013, Nature

    Dr Guy Griebel

  18. Further evidence for the sleep-promoting effects of 5-HT2A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats

    Article • Neuropharmacology, July 2013, Elsevier

    Dr Guy Griebel

  19. Deep brain stimulation in treatment-resistant depression in mice: Comparison with the CRF1 antagonist, SSR125543

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, January 2013, Elsevier

    Dr Guy Griebel

  20. The Vasopressin V 1b Receptor Antagonist SSR149415 in the Treatment of Major Depressive and Generalized Anxiety Disorders

    Article • The Journal of Clinical Psychiatry, October 2012, Physicians Postgraduate Press, Inc

    Dr Guy Griebel

  21. SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents

    Article • Pharmacology Biochemistry and Behavior, August 2012, Elsevier

    Dr Guy Griebel

  22. Awakening properties of newly discovered highly selective H3 receptor antagonists in rats

    Article • Behavioural Brain Research, July 2012, Elsevier

    Dr Guy Griebel

  23. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

    Article • Nature Reviews Drug Discovery, May 2012, Nature

    Dr Guy Griebel

  24. Is there still a future for neurokinin 3 receptor antagonists as potential drugs for the treatment of psychiatric diseases?

    Article • Pharmacology & Therapeutics, January 2012, Elsevier

    Dr Guy Griebel

  25. The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition

    Article • Pharmacology Biochemistry and Behavior, May 2011, Elsevier

    Dr Guy Griebel

  26. The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice

    Article • Pharmacology Biochemistry and Behavior, May 2011, Elsevier

    Dr Guy Griebel

  27. Risk assessment as an evolved threat detection and analysis process

    Article • Neuroscience & Biobehavioral Reviews, March 2011, Elsevier

    Dr Guy Griebel

  28. The Mouse Defense Test Battery: A Model Measuring Different Facets of Anxiety-Related Behaviors

    Article • January 2011, Springer Science + Business Media

    Dr Guy Griebel

  29. SSR181507, a dopamine D2 receptor and 5-HT1A receptor ligand: Evidence for mixed anxiolytic- and antidepressant-like activities

    Article • Pharmacology Biochemistry and Behavior, January 2011, Elsevier

    Dr Guy Griebel

  30. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents

    Article • Psychopharmacology, December 2010, Springer Science + Business Media

    Dr Guy Griebel

  31. Effects of intra-hippocampal injections of the NK2 receptor antagonist saredutant on the elevated plus maze, and the mouse defense test battery

    Article • Neuroscience Letters, November 2010, Elsevier

    Dr Guy Griebel

  32. Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression

    Article • Pharmacology Biochemistry and Behavior, August 2010, Elsevier

    Dr Guy Griebel

  33. Implication of β3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress

    Article • Behavioural Brain Research, January 2010, Elsevier

    Dr Guy Griebel

  34. The Glycine Transporter-1 Inhibitor SSR103800 Displays a Selective and Specific Antipsychotic-like Profile in Normal and Transgenic Mice

    Article • Neuropsychopharmacology, September 2009, Nature

    Dr Guy Griebel

  35. Pro-Cognitive and Antipsychotic Efficacy of the α7 Nicotinic Partial Agonist SSR180711 in Pharmacological and Neurodevelopmental Latent Inhibition Models of Schizophrenia

    Article • Neuropsychopharmacology, January 2009, Nature

    Dr Guy Griebel

  36. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat

    Article • Psychopharmacology, August 2008, Springer Science + Business Media

    Dr Guy Griebel

  37. Drug-Dependent Requirement of Hippocampal Neurogenesis in a Model of Depression and of Antidepressant Reversal

    Article • Biological Psychiatry, August 2008, Elsevier

    Dr Guy Griebel

  38. Corticolimbic Transcriptome Changes are State-Dependent and Region-Specific in a Rodent Model of Depression and of Antidepressant Reversal

    Article • Neuropsychopharmacology, June 2008, Nature

    Dr Guy Griebel

  39. Confirmation of antidepressant potential of the selective β3 adrenoceptor agonist amibegron in an animal model of depression

    Article • Pharmacology Biochemistry and Behavior, June 2008, Elsevier

    Dr Guy Griebel

  40. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models

    Article • Pharmacology Biochemistry and Behavior, March 2008, Elsevier

    Dr Guy Griebel

  41. Chapter 4.6 Genetic factors underlying anxiety-behavior: A meta-analysis of rodent studies involving targeted mutations of neurotransmission genes

    Article • January 2008, Elsevier

    Dr Guy Griebel

  42. Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders

    Article • Neuropsychopharmacology, April 2007, Nature

    Dr Guy Griebel

  43. SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile

    Article • Neuropsychopharmacology, October 2006, Nature

    Dr Guy Griebel

  44. SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia

    Article • Neuropsychopharmacology, August 2006, Nature

    Dr Guy Griebel

  45. An Overview of SSR149415, a Selective Nonpeptide Vasopressin V1b Receptor Antagonist for the Treatment of Stress-Related Disorders

    Article • CNS Drug Reviews, June 2006, Wiley

    Dr Guy Griebel

  46. Editorial [Hot Topic: Neuropeptide Systems as Novel Targets for Psychiatric Disorders (Guest Editor: Guy Griebel) ]

    Article • CNS & Neurological Disorders - Drug Targets, April 2006, Bentham Science Publishers

    Dr Guy Griebel

  47. Antidepressant-Like Effects of the Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat

    Article • Neuropsychopharmacology, February 2006, Nature

    Dr Guy Griebel

  48. Antidepressant-like effects of the vasopressin V1b receptor antagonist SSR149415 in the Flinders Sensitive Line rat

    Article • Pharmacology Biochemistry and Behavior, September 2005, Elsevier

    Dr Guy Griebel

  49. Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic

    Article • Neuropsychopharmacology, June 2005, Nature

    Dr Guy Griebel

  50. Disruption of the Prepulse Inhibition of the Startle Reflex in Vasopressin V1b Receptor Knockout Mice: Reversal by Antipsychotic Drugs

    Article • Neuropsychopharmacology, June 2005, Nature

    Dr Guy Griebel

  51. Non-Peptide Vasopressin V1b Receptor Antagonists as Potential Drugs for the Treatment of Stress-Related Disorders

    Article • Current Pharmaceutical Design, May 2005, Bentham Science Publishers

    Dr Guy Griebel

  52. ENZYMATIC RESOLUTION AND BASE PAIRING PROPERTIES OFD- ANDL-CYCLOHEXENYL NUCLEIC ACIDS (CeNA)

    Article • Nucleosides Nucleotides & Nucleic Acids, April 2005, Taylor & Francis

    Dr Guy Griebel

  53. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

    Article • Biological Psychiatry, February 2005, Elsevier

    Dr Guy Griebel

  54. Defensive Responses to Predator Threat in the Rat and Mouse

    Article • Current Protocols in Neuroscience, January 2005, Wiley

    Dr Guy Griebel

  55. Chapter 4.2 Nonpeptide vasopressin V1b receptor antagonists

    Article • January 2005, Elsevier

    Dr Guy Griebel

  56. Evidence that the Lateral Septum is Involved in the Antidepressant-Like Effects of the Vasopressin V1b Receptor Antagonist, SSR149415

    Article • Neuropsychopharmacology, September 2004, Nature

    Dr Guy Griebel

  57. Nicotine-Associated Cues Maintain Nicotine-Seeking Behavior in Rats Several Weeks after Nicotine Withdrawal: Reversal by the Cannabinoid (CB1) Receptor Antagonist, Rimonabant (SR141716)

    Article • Neuropsychopharmacology, August 2004, Nature

    Dr Guy Griebel

  58. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression

    Article • European Journal of Pharmacology, August 2004, Elsevier

    Dr Guy Griebel

  59. Response to Roesler et al.: Neuropeptides and stress-related disorders – multiple targets and converging concepts

    Article • Trends in Pharmacological Sciences, May 2004, Elsevier

    Dr Guy Griebel

  60. Effects of the CRF1 antagonist SSR125543A on aggressive behaviors in hamsters

    Article • Pharmacology Biochemistry and Behavior, March 2004, Elsevier

    Dr Guy Griebel

  61. Impaired memory following predatory stress in mice is improved by fluoxetine

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, January 2004, Elsevier

    Professor Wissam El-Hage, Dr Guy Griebel

  62. Conditioning and residual emotionality effects of predator stimuli: some reflections on stress and emotion

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, December 2003, Elsevier

    Dr Guy Griebel

  63. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

    Article • Trends in Pharmacological Sciences, November 2003, Elsevier

    Dr Guy Griebel

  64. The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders

    Article • Current Drug Targets - CNS & Neurological Disorders, June 2003, Bentham Science Publishers

    Dr Guy Griebel

  65. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, June 2003, Elsevier

    Dr Guy Griebel

  66. SL651498, a GABAA Receptor Agonist with Subtype-Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms

    Article • CNS Drug Reviews, March 2003, Wiley

    Dr Guy Griebel

  67. The Mouse Defense Test Battery: pharmacological and behavioral assays for anxiety and panic

    Article • European Journal of Pharmacology, February 2003, Elsevier

    Dr Guy Griebel

  68. Functional and Pharmacological Characterization of the First Specific Agonist and Antagonist for the V1b Receptor in Mammals

    Article • Stress, January 2003, Taylor & Francis

    Dr Guy Griebel

  69. Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery

    Article • Neuroscience & Biobehavioral Reviews, December 2001, Elsevier

    Dr Guy Griebel

  70. Effects of SR48968, a selective non-peptide NK 2 receptor antagonist on emotional processes in rodents

    Article • Psychopharmacology, November 2001, Springer Science + Business Media

    Dr Guy Griebel

  71. Measuring normal and pathological anxiety-like behaviour in mice: a review

    Article • Behavioural Brain Research, November 2001, Elsevier

    Dr Guy Griebel

  72. Behavioral and neurochemical changes following predatory stress in mice

    Article • Neuropharmacology, September 2001, Elsevier

    Professor Wissam El-Hage, Dr Guy Griebel

  73. The effects of compounds varying in selectivity as 5-HT1A receptor antagonists in three rat models of anxiety

    Article • Neuropharmacology, September 2000, Elsevier

    Dr Guy Griebel

  74. Subtype-selective benzodiazepine receptor ligands

    Article • January 2000, Springer Science + Business Media

    Dr Guy Griebel

  75. Discriminative Stimulus Effects of Drugs Acting at GABAA Receptors

    Article • Pharmacology Biochemistry and Behavior, October 1999, Elsevier

    Dr Guy Griebel

  76. Behavioral Effects of Acute and Chronic Fluoxetine in Wistar–Kyoto Rats

    Article • Physiology & Behavior, September 1999, Elsevier

    Dr Guy Griebel

  77. Pharmacological studies on synthetic flavonoids: comparison with diazepam

    Article • Neuropharmacology, July 1999, Elsevier

    Dr Guy Griebel

  78. Orphanin FQ, a novel neuropeptide with anti-stress-like activity

    Article • Brain Research, July 1999, Elsevier

    Dr Guy Griebel

  79. Is There a Future for Neuropeptide Receptor Ligands in the Treatment of Anxiety Disorders?

    Article • Pharmacology & Therapeutics, April 1999, Elsevier

    Dr Guy Griebel

  80. Differences in Anxiolytic-Like Profile of Two Novel Nonbenzodiazepine BZ (ϖ) Receptor Agonists on Defensive Behaviors of Mice

    Article • Pharmacology Biochemistry and Behavior, April 1999, Elsevier

    Dr Guy Griebel

  81. Study of the modulatory activity of bz (ω) receptor ligands on defensive behaviors in mice: Evaluation of the importance of intrinsic efficacy and receptor subtype selectivity

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, January 1999, Elsevier

    Dr Guy Griebel

  82. Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs: correlation with changes in monoamine–oxidase activity and monoamine levels

    Article • Neuropharmacology, July 1998, Elsevier

    Dr Guy Griebel

  83. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries

    Article • Neuroscience & Biobehavioral Reviews, November 1997, Elsevier

    Dr Guy Griebel

  84. Risk Assessment Behaviour: Evaluation of Utility in the Study of 5-HT-Related Drugs in the Rat Elevated Plus-Maze Test

    Article • Pharmacology Biochemistry and Behavior, August 1997, Elsevier

    Dr Guy Griebel

  85. An Ethopharmacological Analysis of Selective Activation of 5-HT1A Receptors: The Mouse 5-HT1A Syndrome

    Article • Pharmacology Biochemistry and Behavior, August 1997, Elsevier

    Dr Guy Griebel

  86. Genetic differences in the mouse defense test battery

    Article • Aggressive Behavior, January 1997, Wiley

    Dr Guy Griebel

  87. Genetic differences in the mouse defense test battery

    Article • Aggressive Behavior, January 1997, Wiley

    Dr Guy Griebel

  88. Evidence that the Behaviors in the Mouse Defense Test Battery Relate to Different Emotional States: A Factor Analytic Study

    Article • Physiology & Behavior, November 1996, Elsevier

    Dr Guy Griebel

  89. Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21357

    Article • Pharmacology Biochemistry and Behavior, May 1996, Elsevier

    Dr Guy Griebel

  90. Predator-elicited plight responses in Swiss-Webster Mice: An experimental model of panic attacks

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, February 1996, Elsevier

    Dr Guy Griebel

  91. 5-HT1A agonists modulate mouse antipredator defensive behavior differently from the 5-HT2A antagonist pirenperone

    Article • Pharmacology Biochemistry and Behavior, June 1995, Elsevier

    Dr Guy Griebel

  92. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research

    Article • Pharmacology & Therapeutics, January 1995, Elsevier

    Dr Guy Griebel

  93. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents

    Article • Psychopharmacology, January 1994, Springer Science + Business Media

    Dr Guy Griebel

  94. Some critical determinants of the behaviour of rats in the elevated plus-maze

    Article • Behavioural Processes, April 1993, Elsevier

    Dr Guy Griebel

  95. Prolactin similar to ectopic pituitary isograft restores responsiveness in Snell dwarf mice

    Article • Neuroreport, February 1992, Wolters Kluwer Health

    Dr Guy Griebel

  96. Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice

    Article • Neuroreport, January 1992, Wolters Kluwer Health

    Dr Guy Griebel

  97. m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice

    Article • Neuroreport, October 1991, Wolters Kluwer Health

    Dr Guy Griebel

  98. Behavioral effects of rolipram and structurally related compounds in mice: Behavioral sedation of cAMP phosphodiesterase inhibitors

    Article • Pharmacology Biochemistry and Behavior, June 1991, Elsevier

    Dr Guy Griebel

  99. Comparison of the behavioural effects of an adenosine A1/A2-receptor antagonist, CGS 15943A, and an A1-selective antagonist, DPCPX

    Article • Psychopharmacology, April 1991, Springer Science + Business Media

    Dr Guy Griebel

  100. Behavioural effects of selective A2 adenosine receptor antagonists, CGS 21197 and CGS 22706, in mice

    Article • Neuroreport, March 1991, Wolters Kluwer Health

    Dr Guy Griebel

  101. Serenics fluprazine (DU 27716) and eltoprazine (DU 28853) enhance neophobic and emotional behaviour in mice

    Article • Psychopharmacology, December 1990, Springer Science + Business Media

    Dr Guy Griebel

  102. Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice

    Article • Neuroreport, November 1990, Wolters Kluwer Health

    Dr Guy Griebel

  103. Amino Acid Transmitter Systems

    Article • Wiley

    Dr Guy Griebel

  104. Anxiety disorders

    Article • Cambridge University Press

    Dr Guy Griebel

  105. Anxiety disorders

    Article • Cambridge University Press

    Dr Guy Griebel

  106. Faculty of 1000 evaluation for Noninvasive optical inhibition with a red-shifted microbial rhodopsin.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  107. Faculty of 1000 evaluation for Global optogenetic activation of inhibitory interneurons during epileptiform activity.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  108. Faculty of 1000 evaluation for Astrocyte-derived ATP modulates depressive-like behaviors.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  109. Faculty of 1000 evaluation for Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  110. Faculty of 1000 evaluation for Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  111. Faculty of 1000 evaluation for Virally mediated optogenetic excitation and inhibition of pain in freely moving nontransgenic mice.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  112. Faculty of 1000 evaluation for Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  113. Faculty of 1000 evaluation for Nectin-3 links CRHR1 signaling to stress-induced memory deficits and spine loss.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  114. Faculty of 1000 evaluation for Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  115. Faculty of 1000 evaluation for Diverging neural pathways assemble a behavioural state from separable features in anxiety.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  116. Faculty of 1000 evaluation for The Corticotropin Releasing Hormone-1 (CRH1) Receptor Antagonist Pexacerfont in Alcohol Dependence: A Randomized Controlled Experimental Medicine Study.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel

  117. The Mouse Defense Test Battery: An experimental model of different emotional states.

    Article • American Psychological Association (APA)

    Dr Guy Griebel

  118. Faculty of 1000 evaluation for A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.

    Article • Faculty of 1000, Ltd.

    Dr Guy Griebel